AD/PD 2024 | ALZ-801 in combination with anti-amyloid antibodies for the treatment of Alzheimer’s disease

John Hey, PhD, Alzheon, Inc., Framingham, MA, summarizes the promising therapeutic potential of ALZ-801 for Alzheimer’s disease (AD). ALZ-801 is an investigational small-molecule inhibitor of beta amyloid (Aβ) oligomer formation. Due to its mechanism of action, ALZ-801 may be used as a standalone therapeutic or in combination with other disease-modifying therapies (DMTs). Dr Hey highlights that the safety profile of ALZ-801 is highly favorable for use with both anti-amyloid antibodies, such as lecanemab, as well as symptomatic therapeutics. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.